Strategic partnerships IBT Bioservices has recently announced a commercial distribution partnership with Dyadic Applied BioSolutions, suggesting a receptive channel for co-marketing and expanded product offerings. This indicates potential sales opportunities through partner ecosystems and cross-sell of CRO and biochemical services.

Expanded online storefront A significantly enhanced webstore launched in May 2025 signals improved e-commerce capabilities and a broader catalog. This creates upsell opportunities for researchers needing ready-to-order assays, reagents, and cell lines, as well as potential interest in digital marketing to drive traffic and convert visitors.

In vivo and in vitro breadth IBT offers a wide range of in vitro assays and in vivo models, including over 15 efficacy models for viral and bacterial infections and custom assay development. This breadth presents cross-selling potential to biotech startups and established pharma seeking end-to-end CRO solutions for complex biologics and translational studies.

Unique neutralization capabilities Development of fit-for-purpose cell-based neutralizing assays using Marburg virus pseudovirus platforms highlights specialized assay development expertise. Target sales opportunities include biotechs pursuing novel antiviral or antibody therapeutics requiring validated neutralization readouts.

Global shipping and capacity International shipping of reagents and vivarium services combined with a mid-size team indicates agility to support global clients. This suggests upsell potential for multinational collaborations, expanded service scopes, and programs targeting virtual biotech firms needing scalable CRO support.